Namixin

Namixin Biopharma is a clinical-stage biotechnology company based in Suzhou, China, dedicated to the development of next-generation RNA therapeutics. The company leverages proprietary delivery platforms, including GalNAc-siRNA conjugation for liver targeting and lipid nanoparticle (LNP) technologies for extrahepatic applications, to address unmet needs in metabolic and cardiovascular diseases. Its lead candidate, NMX-101, is a long-acting siRNA targeting PCSK9 designed for the management of hypercholesterolemia. Founded by industry veterans with deep expertise in nucleic acid chemistry, Namixin aims to provide transformative treatments that offer improved safety, efficacy, and patient compliance. The company has secured significant backing from prominent venture capital firms to advance its diverse pipeline of RNAi and mRNA candidates.